StockSelector.com
  Research, Select, & Monitor Thursday, May 23, 2019 12:51:23 PM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Aerie Pharmaceuticals, Inc.$39.28($.83)(2.07%)

  Quote | Chart | Valuations | Sentiment | Industry | News | Earnings | Analysts | More...

Your Target?

Aerie Pharmaceuticals, Inc. has an overall rank of 1267 out of 6892 stocks based on 12 positive rankings and 7 negative rankings.

Positive Rankings
PEGValue
Aerie Pharmaceuticals has a PEG Value of $2,352.86. A stock is commonly considered to be fairly valued when its PE ratio equals its earnings growth rate. The PEG Value is the price where the PE Ratio, based on next year's earnings estimate, divided by the estimated growth rate over the next couple of years equals 1. This implies that if the company maintains its estimated growth rate, that the stock should gain 5,766.01% in the next year. Among companies with a PEG Value above the current stock price, Aerie Pharmaceuticals is ranked 13.
Estimated Revenue Growth
Aerie Pharmaceuticals rank is 39
Target Prices
The average analysts' target price is $80.00 for Aerie Pharmaceuticals using target prices set or adjusted within the past 90 days. Among companies with recent target prices and with the average above the current stock price, Aerie Pharmaceuticals is ranked 105.
Low Put/Call
Aerie Pharmaceuticals has a low Put/Call ratio of 0.07 on all open interest of options expiring in the next 90 days. A low put-to-call ratio indicates there are more bullish investors than bearish investors for the stock. Among companies with a low Put/Call Ratio, Aerie Pharmaceuticals is ranked 174.
Low/Rising MACD
The MACD remains negative, but is rising... suggesting a possible near-term correction. Of companies with a negative, but rising MACD, Aerie Pharmaceuticals is ranked 260.
SSValue
The StockSelector Value for Aerie Pharmaceuticals is $214.83. The StockSelector Value assumes the market consistently prices a stock around a given PE ratio and, therefore, multiplies the average PE (using forward earnings estimates) over the past three years by future earnings estimates. Among companies with a StockSelector Value above the current stock price, Aerie Pharmaceuticals is ranked 269.
Up Ratings Revision
During the past month, the average analyst's rating or recommendation has increased. Among companies that have been upgraded within the past month, Aerie Pharmaceuticals is ranked 459.
Low vPut/Call
Aerie Pharmaceuticals has a low Put/Call ratio of 0.29 on active options expiring within the next 90 days. A low put-to-call ratio indicates there are more bullish investors than bearish investors for the stock. Among companies with a low Put/Call Ratio, Aerie Pharmaceuticals is ranked 529.
Debt-to-Equity
Aerie Pharmaceuticals rank is 572
Highest Cash Growth
Aerie Pharmaceuticals rank is 1077
Up EPS Surprise
Aerie Pharmaceuticals beat the consensus earnings estimate when it last reported quarterly earnings.
Up EPS Surprise
Aerie Pharmaceuticals beat the consensus earnings estimate when it last reported quarterly earnings.
Negative Rankings
Price-to-Sales
Aerie Pharmaceuticals rank is 140
Negative Net Margin
Aerie Pharmaceuticals rank is 194
Negative ROA
Aerie Pharmaceuticals rank is 317
Negative ROE
Aerie Pharmaceuticals rank is 350
Price-to-Book
Aerie Pharmaceuticals rank is 520
90 Day Loss
Aerie Pharmaceuticals rank is 1283
10 Day Loss
Aerie Pharmaceuticals rank is 1945







Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2019 StockSelector.com. All rights reserved.